EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B / E14 Studies Needed for Low‐Risk Modalities?

Yusheng Qu iD, Kim A Henderson, Tod A Harper iD, Hugo M Vargas iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3204 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Yusheng Qu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Research, Translational Safety & Bioanalytical Sciences, Amgen Inc., Thousand Oaks, California, USA. Hauptthemen laut MEDLINE: Arrhythmias, Cardiac, Oligonucleotides. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oligonucleotide therapeutics (ONTs) represent a new modality with unique pharmacological and chemical properties that modulate gene expression with a high degree of target specificity mediated by complementary Watson‐Crick base pair hybridization. To date, the proarrhythmic assessment of ONTs has been influenced by International Conference on Harmonization (ICH) E14 and S7B guidance. To document current hERG/QTc evaluation practices, we reviewed US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) Approval Packages (source: PharmaPendium.com ) and collated preclinical and clinical studies for 17 marketed ONTs. In addition, clinical QTc data from 12 investigational ONTs were obtained from the literature. Of the marketed ONTs, eight were tested in the hERG assay with no inhibitory effect identified at the top concentration (range: 34–3,000 μM) tested. Fourteen of the ONTs were evaluated in nonhuman primate cardiovascular studies with 11 of them in dedicated telemetry studies. No effect on QTc intervals were observed (at high exposure multiples) in all studies. Clinically, four ONTs were evaluated in TQT studies; an additional six ONTs were assessed by concentration‐QTc interval analysis, and six by routine safety electrocardiogram monitoring. None of the clinical studies identified a QTc prolongation risk; the same was true for the 12 investigational ONTs. A search of the FDA Adverse Event Database indicated no association between approved ONTs and proarrhythmias. Overall, the collective weight of evidence from 29 ONTs demonstrate no clinical proarrhythmic risk based on data obtained from ICH S7B/E14 studies. Thus, new ONTs may benefit from reduced testing strategies because they have no proarrhythmic risk, a similar cardiac safety profile as monoclonal antibodies, proteins, and peptides.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arrhythmias, CardiacOligonucleotidesAnimalsHumansDrug ApprovalElectrocardiographyRisk AssessmentUnited StatesUnited States Food and Drug Administration

Substanzen

Oligonucleotides

Autor:innen und Institutionen

  • Amgen Research, Translational Safety & Bioanalytical Sciences, Amgen Inc., Thousand Oaks, California, USA.

ORCID-Profile: Yusheng Qu, Tod A Harper, Hugo M Vargas

Zitieren

APA

Qu, Y., Henderson, K. A., Harper, T. A., & Vargas, H. M. (2024). Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B / E14 Studies Needed for Low‐Risk Modalities?. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3204

Vancouver

Qu Y, Henderson KA, Harper TA, Vargas HM. Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B / E14 Studies Needed for Low‐Risk Modalities?. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3204

BibTeX
@article{Qu2024,
  author = {Qu, Yusheng and Henderson, Kim A and Harper, Tod A and Vargas, Hugo M},
  title = {Scientific Review of the Proarrhythmic Risks of Oligonucleotide Therapeutics: Are Dedicated ICH S7B / E14 Studies Needed for Low‐Risk Modalities?},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3204}
}
Kostenlos starten →